IDEXX Laboratories Price Targets Cut by Piper Sandler, Barclays, UBS to $730-$800 Range
Three analysts cut their IDEXX Laboratories price targets: Piper Sandler trimmed to $750 from $775, Barclays to $800 from $850 and UBS to $730 from $750. Each firm maintained Neutral or Overweight ratings after citing underwhelming fiscal Q4 results, muted Q1 growth outlook and softer 2026 margins.
1. Piper Sandler Update
Piper Sandler lowered its price target to $750 from $775 with a Neutral rating after rolling forward estimates to 2027 and adjusting multiples based on IDEXX's quarterly results.
2. Barclays and UBS Price Target Adjustments
Barclays reduced its price target to $800 from $850 and maintained an Overweight rating, noting that the fiscal Q4 outlook underwhelmed. UBS cut its target to $730 from $750 and kept a Neutral rating after mixed signals from Q4 performance.
3. Analyst Concerns and Outlook
Analysts highlighted early diagnostic service growth among aging "pandemic puppies" and pricing strength but flagged muted fiscal Q1 growth, slower Year 2 inVue placements and a softer 2026 gross margin outlook with macro headwinds.